Association of antibiotic-consumption patterns with the prevalence of hematological malignancies in European countries.

Hematological malignancies are considered the fifth most common cancer in the world. Several risk factors and probable etiological agents have been suspected in the pathomechanism of those malignancies as infections, chemicals, irradiation, etc., and recently, the contribution of the altered gut flora, dysbiosis, was identified also as a possible additional factor to the existing ones.

Publication of clinical trials on medicinal products: follow-up on trials authorized in Hungary.

Background: Clinical research should provide reliable evidence to clinicians, health policy makers, and researchers. The reliability of evidence will be assured once study planning, conducting, and reporting of results are transparent. The present research investigates publication rates, time until publication, and characteristics of clinical trials on medicinal products associated with timely publication of results, measures of scientific impact, authorship, and open access publication.

A New and Validated, Randomised, Controlled Placebo Water Development Trial for Medicinal Water-based Research.

Background/aim: To develop and validate an easy-to-use and cheap method capable of producing placebo from tap water for medicinal water efficacy trials.

Patients And Methods: Patients were divided into two groups, medicinal water and tap water group. A single 20-minute-long treatment was performed in bathtubs.

Inverse association between use of broad spectrum penicllin with beta-lactamase inhibitors and prevalence of type 1 diabetes mellitus in Europe.

Increasing incidence of type 1 diabetes is supposed to be induced by environmental factors. Microbiome modulated by antibiotics seems to serve as one of the environmental factors which could influence the development of T1DM. Mitochondria, as autochthonous environmental bacteria living in our cells, and other bacteria share many common enzymes including beta-lactamases and it is supported by evidence that some beta-lactamase inhibitors are able to interact with counterpart enzymes.